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http://dx.doi.org/10.1016/j.ccell.2015.08.013SUMMARYAdenosine-to-inosine (A-to-I) RNA editing is a widespread post-transcriptional mechanism, but its genomic
landscape and clinical relevance in cancer have not been investigated systematically. We characterized
the global A-to-I RNA editing profiles of 6,236 patient samples of 17 cancer types from The Cancer Genome
Atlas and revealed a striking diversity of altered RNA-editing patterns in tumors relative to normal tissues.We
identified an appreciable number of clinically relevant editing events, many of which are in noncoding re-
gions. We experimentally demonstrated the effects of several cross-tumor nonsynonymous RNA editing
events on cell viability and provide the evidence that RNA editing could selectively affect drug sensitivity.
These results highlight RNA editing as an exciting theme for investigating cancer mechanisms, biomarkers,
and treatments.INTRODUCTION
RNA editing is a widespread post-transcriptional mechanism
that confers specific and reproducible nucleotide changes in
selected RNA transcripts (Bass, 2002; Keegan et al., 2001). As
for functional consequences, RNA editing events can result in
missense codon changes (Maas and Rich, 2000), modulation
of alternative splicing (Rueter et al., 1999), or modification of
regulatory RNAs (Kawahara et al., 2007; Tomaselli et al., 2015)
and their binding sites (Liang and Landweber, 2007). In humans,Significance
ADAR-mediated A-to-I RNA editing represents a widespread, p
to engender genomic diversity by reproducibly changing RNA s
The role of RNA editing in human cancer is only beginning to
cancer types. Our systematic analysis of RNA editing across
RNA editing events associated with clinical characteristics of tu
effects on cell viability and drug sensitivity. Thus, aberrant RNA
ibly alter protein or regulatory RNA sequences that could act a
targets in cancer.
Cthe most common type of RNA editing is adenosine to inosine
(A to I) (Piskol et al., 2013), which is catalyzed by ADAR enzymes
(Bass et al., 1997). Despite some issues in earlier attempts,
recently several groups have developed computational
methods for accurately detecting A-to-I RNA editing from
next-generation sequencing data on a large scale (Bahn et al.,
2012; Peng et al., 2012; Ramaswami et al., 2012, 2013). As a
result, more than 1 million A-to-I RNA editing sites have been
confidently detected in the human genome (Bazak et al.,
2014; Ramaswami et al., 2013). However, the vast majority ofhylogenetically conserved, post-transcriptional mechanism
equences without a concomitant change in DNA sequences.
emerge from early studies of individual candidates in a few
17 cancer types demonstrates an appreciable number of
mors and patient outcomes, some of which show functional
editing provides an underexploredmechanism to reproduc-
s drivers and represent potential biomarkers or therapeutic
ancer Cell 28, 515–528, October 12, 2015 ª2015 Elsevier Inc. 515
Table 1. Summary of TCGA RNA-seq Data Used in This Study
Cancer Type Name
(TCGA Code)
No. of Normal
Samples
No. of Tumor
Samples
Sequence
Strategy
Read
Length
Average Mappable
Reads
No. of Informative
Editing Sites
Colorectal cancer (CRC) 0 228 single end 76 21,793,066 8,493
Uterine corpus endometrioid
carcinoma (UCEC)
4 316 single end 76 25,324,332 14,217
Glioblastoma multiforme (GBM) 0 154 paired end 76 106,403,279 37,934
Lung adenocarcinoma (LUAD) 58 488 paired end 48 133,297,582 54,362
Liver hepatocellular carcinoma
(LIHC)
50 200 paired end 48 139,117,210 23,540
Bladder urothelial carcinoma
(BLCA)
19 252 paired end 48 144,059,158 39,270
Kidney renal papillary cell
carcinoma (KIRP)
30 198 paired end 48 146,793,890 36,686
Prostate adenocarcinoma (PRAD) 52 374 paired end 48 147,246,105 43,078
Brain lower grade glioma (LGG) 0 486 paired end 48 149,851,835 51,806
Head and neck squamous cell
carcinoma (HNSC)
42 426 paired end 48 157,436,457 35,510
Cervical squamous cell carcinoma
and endocervical
adenocarcinoma (CESC)
3 196 paired end 48 161,207,521 32,797
Breast invasive carcinoma (BRCA) 105 837 paired end 50 161,673,379 76,555
Kidney renal clear cell carcinoma
(KIRC)
67 448 paired end 50 166,049,114 63,717
Stomach adenocarcinoma (STAD) 33 285 paired end 75 169,720,033 26,389
Lung squamous cell carcinoma
(LUSC)
17 220 paired end 50 171,002,267 36,822
Thyroid carcinoma (THCA) 59 498 paired end 48 171,399,819 52,701
Kidney chromophobe (KICH) 25 66 paired end 48 174,113,816 22,317these sites are in noncoding and repetitive element regions of
the genome and have unknown functional relevance. Therefore,
the research focus on RNA editing has moved from the identifi-
cation of novel sites to characterization of the mechanisms by
which they mediate their functions and their consequences on
cellular function.
To date, a critical role of A-to-I RNA editing in human cancer
has been reported for only individual examples. In prostate can-
cer, A-to-I RNA editing in the androgen receptor impairs the pro-
tein’s ability to interact with androgenic or anti-androgenic
ligands (Martinez et al., 2008); in liver cancer, the edited form of
AZIN1 has a stronger affinity for antizyme and induces cyto-
plasmic-to-nuclear translocation ofAZIN1, anda lowediting level
is sufficient to confer more aggressive tumor behavior (Chen
et al., 2013); in colorectal cancer (CRC), A-to-I RNA editing in
RHOQ promotes the invasion potential (Han et al., 2014); and in
glioblastoma, ADAR2-mediated RNA editing in CDC14B modu-
lates the Skp2/p21/p27 pathway and plays a critical role in the
pathogenesis of this disease (Galeano et al., 2013). Despite these
intriguing findings, the global pattern of A-to-I RNA editing in hu-
man cancer genomes has not been systematically characterized,
and the functional importance and clinical relevance of RNA edit-
ing in cancer remain largely unknown. Here, we aimed to address
these questions through a systematic analysis of A-to-I RNA ed-
iting events using RNA-sequencing data from The Cancer
Genome Atlas (TCGA) project (Weinstein et al., 2013).516 Cancer Cell 28, 515–528, October 12, 2015 ª2015 Elsevier Inc.RESULTS
Overview of A-to-I RNA Editing Patterns across Major
Cancer Types
To perform a comprehensive, high-quality analysis of A-to-I RNA
editing in cancer genomes, we developed a computational pipe-
line based on 1.4 million high-confidence RNA editing sites
annotated in the Rigorously Annotated Database of A-to-I RNA
Editing (RADAR) (Ramaswami and Li, 2014) (Figure S1A). The
RNA editing sites in RADAR were collected from recent tran-
scriptome-wide RNA editing identification studies and under-
went extensive manual curation. We further applied a series of
filters to remove the potential contamination of SNPs or somatic
mutations (Experimental Procedures). Thus, this RNA editing
data set represents a reliable and global candidate set to start
with. FromTCGARNA sequencing (RNA-seq) data, we assessed
the RNA editing signals at these candidate sites in 6,236 samples
of 17 cancer types or related normal tissues (Table 1 and Fig-
ure 1A). For each cancer type, we detected a large number of
RNA editing candidate sites with editing signals, but many of
them were sufficiently covered only in a limited sample set.
Therefore, we defined ‘‘informative’’ RNA editing sites as those
sites with detected signals and coverage R103 in R30 tumor
samples (and related normal samples) for a cancer type (Exper-
imental Procedures) and focused on these sites in subsequent
analyses to ensure adequate statistical power. The number of
AB
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Figure 1. Overview of A-to-I RNA Editing Patterns in Human Cancer
(A) Numbers of TCGA tumor and normal samples analyzed in this study.
(B) Correlation between the number of total mappable RNA-seq bases and the number of informative RNA editing sites across different cancer types.
(C) The editing-level distributions at informative editing sites in different cancer types. Dashed and solid lines denote average and median for each cancer type,
respectively.
(D) The distributions of informative RNA editing sites in different types of RNA regions.
See Table 1 for definitions of abbreviations of cancer types. See also Figure S1.informative RNA editing sites per cancer type ranged from 8,493
in CRC to 76,555 in breast invasive carcinoma (BRCA) (Fig-
ure 1B). This large variation among cancer types is mainly
because (1) the number of tumor samples per cancer type varied
markedly (from 66 in kidney chromophobe [KICH] to 837 in
BRCA; Table 1) and (2) the number of mappable reads per sam-
ple varied greatly among cancer types because of different
sequencing strategies (from 22 million in CRC to 174 million in
KICH; Table 1). Indeed, across the 17 cancer types, the number
of informative editing sites showed a strong linear correlation
with the total number of mappable bases or the total number
of mappable reads (Figure 1B, Pearson’s correlation [R] = 0.84,
p = 2.0 3 105, Spearman’s correlation [Rs] = 0.75, p = 7.4 3
104; Figure S1B, R = 0.89, p = 2.0 3 106, Rs = 0.82, p =
7.0 3 105). These results also indicate that the informative
editing sites we identified show no significant bias toward one
or a few well-studied cancer types.
We first quantified the editing levels at the informative RNA ed-
iting sites (defined as the proportion of edited reads among the
total mapped reads at a given site in a TCGABAMfile). As a qual-City control, we randomly selected a few samples, remapped the
raw RNA-seq reads using the previously established mapping
pipeline that can accurately detect both Alu and non-Alu RNA
editing events (Ramaswami et al., 2012, 2013), and obtained
very consistent RNA-editing levels (Rs > 0.93). Thus, for the infor-
mative edited sites surveyed, the RNA-seq mapping procedures
used had little effect on the quantification of RNA-editing levels.
Figure 1C shows the overall editing-level distributions at informa-
tive RNA editing sites in different cancer types (Figure S1C
shows the distributions in normal tissues). We next examined
the distribution of these editing sites in different types of tran-
scribed regions (Figure 1D). Across different cancer types,
most of the informative RNA editing sites were in 30 UTRs and in-
tronic regions, as observed previously in mouse tissues (Gu
et al., 2012), but the editing sites in coding regions were relatively
limited (Figure S1D shows the numbers of nonsynonymous and
synonymous RNA editing sites in different cancer types).
Furthermore, we did not detect any correlation between RNA-
editing level and the local GC content (Figure S1E). Because
our analysis was based on RNA-seq data, the observed genomicancer Cell 28, 515–528, October 12, 2015 ª2015 Elsevier Inc. 517
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distribution of informative RNA editing sites could be affected by
the coverage bias of themRNA-seq platform. However, because
of the large number of candidate editing sites examined, we still
obtained sufficient sampling power to survey RNA editing activ-
ities in different transcribed regions.
Diversity of RNA Editing Patterns in Tumors Relative
to Normal Samples
The global RNA editing differences between cancer samples and
related normal tissues remain largely uncharacterized, and pre-
vious studies have suggested that this is a complex topic (Fuma-
galli et al., 2015; Jiang et al., 2013; Maas et al., 2001; Nemlich
et al., 2013; Qin et al., 2014; Tomaselli et al., 2015). For example,
an earlier study found reduced editing in brain tumors (Paz et al.,
2007), while a recent study suggested amixture of gene-specific
hyper- and hypo-editing activities in liver cancer (Chan et al.,
2014). However, these studies were either based on a small
set of RNA editing sites or were limited to single cancer types.
To obtain a comprehensive view of RNA editing patterns in tumor
samples, we focused on 12 tumor types with available RNA-seq
data for matched normal tissues from the same patients (Fig-
ure 2A). For each cancer type, we identified RNA editing sites
with significantly differential editing activity betweenmatched tu-
mor and normal samples (paired Wilcoxon test, false discovery
rate [FDR] < 0.05, andmean editing-level difference among com-
parison groups [Diff]R 5%). Although with this criterion, the ed-
iting levels at most sites remained similar, we observed a great
diversity of ‘‘altered’’ RNA editing patterns across these cancer
types: significant numbers of RNA editing sites showed over-ed-
iting patterns in head and neck squamous cell carcinoma, BRCA,
thyroid carcinoma, and lung adenocarcinoma tumors, while sig-
nificant numbers of editing sites showed under-editing patterns
in KICH and kidney renal papillary cell carcinoma tumors.
To identify the molecular determinants underlying these pat-
terns, we performed two complementary analyses, one focusing
on the general pattern across cancer types and the other on the
editing abundancewithin each cancer type.We first analyzed the
correlations of ADAR expression with the ‘‘net’’ proportion of
over-editing RNA sites (defined as the percentage of over-edit-
ing sites minus the percentage of under-editing sites) and found
that the proportion was highly correlated with the relative ADAR1
mRNA expression level (defined as the fold change relative to
normal samples) (Rs = 0.70, p = 0.014; Figure 2B) but not with
that of ADAR2 (Rs = 0.38, p = 0.22; Figure 2B) or ADAR3 (Rs =
0.007, p = 0.99; Figure 2B). Figures 2C and 2D show the
detailed RNA editing change patterns in two representative can-
cer types. In BRCA, 12,770 (16.7%) informative RNA editing sites
showed significant over-editing in the tumor samples comparedFigure 2. Comparison of the Overall A-to-I RNA Editing Patterns betw
(A) Numbers of over-editing sites (red) and under-editing sites (blue) across diffe
(B) The correlation between the ‘‘net’’ proportion of over-editing sites (defined as t
sites [blue]) and the relative mRNA expression of ADAR1 (left), ADAR2 (middle), a
meaningful relation, the rank-based Spearman correlations were used and plotte
(C) Distribution of editing-level difference in BRCA relative to matched normal bre
tumor and blue in normal).
(D) Distribution of editing level difference in KICH samples relative to matched no
In (C) and (D), the paired Wilcoxon test was used to assess the difference betwee
with whiskers extending to the most extreme data point within 1.5 interquartile r
cancer types. See also Table S1.
Cwith matched normal samples, whereas only 553 (1.2%) showed
significant under-editing in tumor samples (pairedWilcoxon test,
FDR < 0.05; Figure 2C, left). In contrast, in KICH, only 110 infor-
mative RNA editing sites (0.5%) showed over-editing in the tu-
mor samples, whereas 4,318 (19.3%) showed under-editing in
tumor samples (paired Wilcoxon test, FDR < 0.05; Figure 2D,
left). Indeed, ADAR1 mRNA expression was much higher in
BRCA than in matched normal samples (fold change = 1.81,
paired Wilcoxon test, p < 2.2 3 1016; Figure 2C, right), while
ADAR1was significantly under-expressed inKICH (fold change=
0.76, paired Wilcoxon test, p = 1.6 3 104; Figure 2D, right). We
further performed sample-based analysis within each cancer
type and found that the number of informative sites with editing
signals showed the strongest correlation with the ADAR1mRNA
expression among the three ADAR enzymes (Table S1). These
results suggest that the global altered RNA editing patterns in tu-
mors are more likely to be affected by ADAR1 than the other two
editing enzymes. However, because the mRNA expression of
ADAR may not directly reflect enzyme editing activity (Wahlstedt
et al., 2009), and the dimer formation and the interactions among
the ADAR enzymes could be important for editing activity (Chen
et al., 2000; Chilibeck et al., 2006; Cho et al., 2003), further efforts
are required to elucidate the relative contributions of the three
ADAR enzymes to the observed RNA editing patterns.
An Appreciable Level of Clinically Relevant RNA Editing
Sites in Various Cancer Types
Given the large number of A-to-I RNA editing events observed
across tumor types and distinct editing patterns at some sites
between tumor and normal tissues, a fundamental question is
what fraction of RNA editing events in tumors are functionally
tumorigenic or clinically valuable. To address this question, we
focused on the RNA editing sites showing correlations with tu-
mor subtype, clinical stage, and patient survival. Clinical stage
and patient survival are well-established clinical variables, while
tumor subtype often facilitates clinical decisions. In a sense, they
all characterize intertumoral heterogeneity among the same dis-
ease. Thus, we referred to RNA editing sites showing non-
random editing patterns with regard to these biologically and
clinically meaningful parameters as ‘‘clinically relevant editing
sites.’’ Specifically, we identified such sites within each cancer
type using three complementary computational analyses (Fig-
ure 3A): (1) differential analysis of RNA editing level among estab-
lished tumor subtypes (FDR < 0.01, DiffR 5%), which identified
2,660 RNA editing sites in total; (2) differential analysis of RNA
editing level among tumor stages (FDR < 0.05, DiffR 5%), which
identified 684 RNA editing sites in total; and (3) correlation anal-
ysis of RNA editing level with patient overall survival (FDR < 0.05,een Paired Tumor and Normal Samples
rent cancer types.
he percentage of over-editing sites [red] minus the percentage of under-editing
nd ADAR3 (right) (fold change relative to normal tissues). To robustly detect a
d.
ast tissue samples (left) and the mRNA expression level of ADAR1 (right) (red in
rmal kidney samples.
n paired tumor and normal samples. The boxes show the median ± 1 quartile,
ange from the box boundaries. See Table 1 for definitions of abbreviations of
ancer Cell 28, 515–528, October 12, 2015 ª2015 Elsevier Inc. 519
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Figure 3. Identification and Patterns of Clinically Relevant RNA Editing Sites
(A) Overview of clinically relevant RNA editing sites identified by three complementary computational analyses: differential analysis among tumor subtypes,
differential analysis among tumor stages, and correlation analysis with patient overall survivals. An explicative cartoon is shown for illustration purposes.
(B–D) Statistical significance for the enrichment or depletion patterns of clinically relevant RNA editing sites through coverage-dependent permutation tests
across 12 tumor types for different types of RNA regions: gene annotation (B), non-repetitive (C), non-Alu repetitive and Alu elements, and evolutionary con-
servation (D). ncRNA, non-coding RNA.
See Table 1 for definitions of abbreviations of cancer types. See also Table S2.Diff R 5%), which identified 1,130 RNA editing sites in total.
Among the 17 cancer types, 12 cancers contained such clinically
relevant sites, ranging from 4 in prostate adenocarcinoma to
2,059 in BRCA (Table S2). To rule out the potential confounding
effect of tumor purity, we repeated the analysis using
ABSOLUTE-based (Carter et al., 2012) tumor purity as a covari-
ate. For the 9 cancer types with available tumor purity data, we
found that 97.9% of the clinically relevant sites originally identi-
fied still remain significant (Table S2).We also calculated the cor-
relation of ADAR expression levels with tumor purity and found
no strong correlation (Table S2). Therefore, tumor purity ap-
peared to have little effect on our results.
In order to investigate the distributions of clinically relevant ed-
iting sites in different types of RNA regions, we classified the
RNA editing sites from three parallel perspectives: gene annota-
tion, sequence repetitive elements, and evolutionary conserva-
tion. Because the power to detect clinically relevant editing sites
in our analysis was affected by sample size and quality of clinical
data (e.g., the follow-up time) in a given cancer type, we exam-
ined the distribution patterns for each cancer type separately.
Furthermore, given the potential effects of coverage bias in
different RNA regions due to gene expression or the mRNA-
seq platform, instead of directly comparing the proportions of
clinically relevant RNA editing sites among different RNA re-520 Cancer Cell 28, 515–528, October 12, 2015 ª2015 Elsevier Inc.gions, we performed a coverage-dependent permutation test
to assess the enrichment and depletion patterns (Experimental
Procedures). In terms of gene annotation, we found that clinically
relevant RNA editing sites tend to be in noncoding RNAs as well
as in nonsynonymous and intronic regions in some cancer types
(Figure 3B). In terms of sequence repetitive elements, clinically
relevant sites show consistent depletion patterns inAlu elements
(Figure 3C). In terms of evolutionary conservation, clinically rele-
vant sites tend to be conserved among humans, chimpanzees,
and macaques (Figure 3D). Together, these analyses based on
different types of RNA-region classification help understand
which factors affect the overall distributions of clinically relevant
RNA editing sites.
‘‘Driver’’ Functional Effects of Clinically Relevant
Nonsynonymous RNA Editing Events
Because clinically relevant RNA editing events at nonsynony-
mous sites could directly result in amino acid changes, we
focused on these RNA editing sites and assessed their functional
effects experimentally. To boost the discovery power, we per-
formed the above analyses for nonsynonymous RNA editing
sites with a relaxed FDR cutoff and identified 35 RNA editing
sites with potential clinical relevance (FDR < 0.2, Diff R 5%;
Table S3). Interestingly, 8 of these RNA editing events (22.9%)
showed clinically relevant patterns in more than one cancer type
(Figures 4A and S2). This pan-cancer analysis suggests that
some A-to-I nonsynonymous RNA editing may be a ‘‘master’’
driver event and play a critical functional role in different tumor
contexts. We focused on four top editing candidate sites
(S367G in AZIN1, I164V in COPA, I635V in COG3, and R764G
in GRIA2) for further investigation (Figures 4A and S2B). The
functional effects of RNA editing at the residue S367G in
AZIN1 (identified in eight cancer types by our analysis; Figures
4B and S2C) have been characterized in liver cancer (Chen
et al., 2013). Differential editing activity at I164V in COPA (identi-
fied in seven cancer types; Figures 4C and S2D) between tumor
and normal samples has been reported in liver cancer (Chan
et al., 2014) but has not been functionally characterized. I635V
at COG3 (identified in six cancer types Figures 4D and S2E)
was only reported in a recent RNA-editing methodology study
(Ramaswami et al., 2012). GRIA2 (also known as GluR-B)
contains two known RNA editing sites: the Q607R editing in
the second transmembrane domain is well studied (Herb et al.,
1996; Higuchi et al., 1993) but has insufficient coverage in our
data set; the role of R764G (identified in two cancer types; Fig-
ure 4E) has not been functionally characterized in cancer. We
confirmed the occurrence of these RNA editing events in an
independent set of breast tumor samples using an orthogonal
Sequenom approach (Figures 5A and S3A).
Given the availability of high-quality antibodies, we assessed
the functional effects of the editing events in AZIN1, GRIA2,
and COG3 using various functional assays. To examine the ef-
fects on cell proliferation or survival, we performed cell viability
assays (upon overexpression) in MCF10A cells, a normal human
breast epithelial cell line. Given similar levels of wild-type (WT)
and edited proteins (Figure S3B), the edited AZIN1 (AZIN1S367G),
GRIA2 (GRIA2R764G), and COG3 (COG3I635V) significantly
increased cell survival relative to the WT gene (t test, p < 0.05;
Figure 5B; see Experimental Procedures). We obtained similar
results of cell viability assays on the basis of cell counting (Fig-
ure S3C). Because these RNA editing events show cross-tumor
clinical relevance, we further examined their effects in a different
lineage. We performed similar viability assays in Ba/F3 cells,
which is a murine leukemia cell line and an established drug
screening platform for subsequent investigation (Cheung et al.,
2014; Liang et al., 2012), and observed the same patterns
(t test, p < 0.05; Figure 5C). To examine the effects on cell sur-
vival, we assessed levels of active caspase-3 in MCF10A and
found no significant changes (Figure S3D). These results were
confirmed by a cell death detection ELISA kit (data not shown).
To examine the effects on cell migration, we performed wound
healing assays in MFC10A and observed no substantial effects
(Figure S3E).
Therapeutic Liability of Clinically Relevant
Nonsynonymous RNA Editing Sites
A critical question about RNA editing is whether some RNA edit-
ing could affect the response of cancer therapies. This question
has significant clinical implications but has never been investi-
gated. Given their confirmed ‘‘driver’’ behaviors in Ba/F3 (Fig-
ure 5C), we focused on the RNA editing in AZIN1, GRIA2, and
COG3 and examined whether these events alter drug sensitivity
using a high-throughput Ba/F3 differential cytotoxicity screenC(Cheung et al., 2014; Quayle et al., 2012). Ba/F3 cells depend
on interleukin-3 (IL-3) for proliferation but readily become IL-3 in-
dependent in the presence of an oncogene or oncogenic event
(Liang et al., 2012). We screened 145 compounds targeting ma-
jor signaling pathways in Ba/F3 addicted to these RNA editing
events (in the absence of IL-3) and performed a ‘‘counterscreen’’
with the same Ba/F3 cells cultured with exogenous IL-3 to con-
trol for the cytotoxic activity of the compounds. In addition, we
used a spontaneously transformed Ba/F3 cell line (originally
transfected with PIK3R1 but not expressing significant levels of
PIK3R1) as negative controls. Strikingly, compared with the
WT genes, the edited genes selectively affected the sensitivity
of Ba/F3 cells to several targeted therapeutics, including
AZIN1S367G for the IGF-1R inhibitor BMS536924, GRIA2R764G
for MEK inhibitors CI1040 and PD0325901, and COG3I635V for
MEK inhibitors CI1040, PD0325901, and trametinib (Figure 6A
shows representative examples).
Furthermore, we examined the editing levels of the 35 clinically
relevant nonsynonymous RNA editing sites (Table S3) in cell lines
from the Cancer Cell Line Encyclopedia (CCLE) (Barretina et al.,
2012) and examined their correlations with the sensitivity data
(half maximal inhibitory concentration [IC50]) of 24 drugs avail-
able at the CCLE portal. Interestingly, we found that the editing
levels of 16 RNA editing sites were significantly correlated with
drug sensitivity (FDR < 0.1; Figure 6B). Furthermore, across
RNA editing sites, the drug clustering analysis showedmeaning-
ful patterns: three chemotherapy agents, paclitaxel, irinotecan,
and topotecan, were clustered together and their sensitivities
were associated with the editing in AZIN1 and other sites; erloti-
nib was in the same cluster as the HER2 agent lapatinib; two RAF
inhibitors, PLX4720 and RAF265, were adjacent to each other;
and two MEK inhibitors, AZD6244 and PD0325901, were tightly
correlated. These results suggest that the effects of RNA editing
on drug response are not limited to the cases we examined.
DISCUSSION
The advent of next-generation sequencing data has drawnwide-
spread attention to the analysis of RNA editing (Li et al., 2011;
Peng et al., 2012; Piskol et al., 2013; Ramaswami et al., 2012,
2013); however, these studies have mainly focused on RNA edit-
ing events in normal tissues. More recently, a functional role for
RNA editing in tumorigenesis has begun to emerge, but related
studies have been limited to individual examples. The present
study represents a systematic investigation of the global pattern
and clinical relevance of A-to-I RNA editing across a broad range
of cancer types and normal tissues.
The number of A-to-I RNA editing sites in humans is huge, but
most sites exhibit editing at very low levels (Bazak et al., 2014),
leading to a great challenge in detecting editing sites in a
comprehensive manner. To ensure high-quality analysis, we
started with the high-confidence RNA editing sites reported in
previous studies rather than calling novel editing sites without
prior knowledge. We focused on RNA editing events with de-
tected editing signals in multiple TCGA samples and further
filtered those with potential mutational signals at the DNA level.
Although ‘‘false’’ RNA-editing sites due to SNPs or mutations
might not be completely removed, such noise in our data should
be very rare. Because of the large number of RNA editingancer Cell 28, 515–528, October 12, 2015 ª2015 Elsevier Inc. 521
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candidates identified in normal tissues in the RADAR database,
we obtained sufficient numbers of RNA editing sites to assess
the global patterns of A-to-I RNA editing. Furthermore, the
strong linear correlation between informative editing sites per
cancer type and the total number of mapped reads (or bases)
across cancer types indicates that our RNA editing sets are
not biased toward well-studied cancer types.
The rich TCGA data set allowed researchers to address some
important questions about RNA editing on a large scale (Paz-
Yaacov et al., 2015). We revealed a diversity of altered RNA edit-
ing events in tumor samples relative to normal tissues, which
correlates best with the ADAR1 expression level globally. Note
that this observation does not rule out the important role of
ADAR2-mediated editing events in specific cancer types, as
demonstrated in previous studies (Cenci et al., 2008; Galeano
et al., 2013; Maas et al., 2001; Tomaselli et al., 2015). On the ba-
sis of the correlations of RNA editing levels with tumor subtype,
stage, or survival, we detected an appreciable number of RNA
editing sites with potential clinical relevance (3.5% of the total
informative RNA editing sites examined). These editing sites
showmarked editing difference for distinct patient groups within
a cancer type, and they may represent promising biomarker
candidates for further assessment. An alternative way to infer
clinically relevance could be based on levels of edited tran-
scripts. However, unlike the editing level, which is a parameter
independent from the expression level of the edited gene, the
levels of edited transcripts are linked to the gene expression
level itself. Indeed, we observed that for a large proportion of
RNA editing sites with clinical correlations based on the level
of edited transcripts, their gene expression levels also showed
corresponding correlations, suggesting the potential confound-
ing effects of gene expression on detecting clinical relevance.
Therefore, we focused on the editing-level-based clinically rele-
vant sites in this study. Our data sets (both raw data and clini-
cally relevant sites) have been made publically available through
Synapse (Omberg et al., 2013) and thus provide a valuable
resource for systematically dissecting the clinical utility of RNA
editing.
Importantly, we experimentally investigated the functional ef-
fects of several nonsynonymous RNA editing events with poten-
tial clinical relevance across multiple tumor types, including the
well-studied editing site in AZIN1 and the other two previously
functionally uncharacterized RNA editing sites in COG3 and
GRIA2. Moreover, our study provides the evidence that a spe-
cific RNA editing event could selectively affect therapeutic re-
sponses. We demonstrated that the RNA editing event in
COG3 and GRIA2 increased sensitivity to some targeted
agents, whereas the editing in AZIN1 engendered decreased
sensitivity. Mutations in cancer genes can increase or decrease
sensitivity to the same therapeutic agent on the basis of whereFigure 4. Clinical Relevance of Nonsynonymous A-to-I RNA Editing Si
(A) The clinical relevance of eight nonsynonymous RNA editing sites identified in
nificant, the red box indicates the significant differential editing among tumor sub
editing among stages (FDR < 0.2, DiffR 5%), the blue box indicates the associa
(B–E) Representative plots showing clinical relevance of nonsynonymous RNA e
microsatellite instability) (B), COPAI164V (stomach adenocarcinoma [STAD] subt
nomically stable; MSI, microsatellite instability) (C), COG3I635V (D), and GRIA2R76
most extreme data point within 1.5 interquartile range from the box boundaries.
See Table 1 for definitions of abbreviations of cancer types. See also Figure S2
Cthey are located in the targeted pathway. For example, muta-
tions in the EGFR increase sensitivity to drugs targeting the
EGFR. However, mutations in KRAS, which is clearly a driver,
can result in resistance to EGFR inhibitors. Furthermore, if the
editing is a neomorph, it could either increase or decrease to
the sensitivity to a specific drug. Thus, some RNA editing events
may be functionally equivalent to ‘‘driver’’ mutations, making a
notable contribution to tumor initiation and growth as well as
playing a critical role in response to cancer therapy. Together,
our findings highlight RNA editing as an exciting theme for
investigating cancer mechanisms, identifying biomarkers, and
developing therapeutic targets. Further efforts should be
made to characterize the function of other clinically relevant
RNA editing events (especially those in noncoding regions), to
elucidate the interactions of these editing events with other
types of molecular aberrations, and to investigate their utility
in clinical practice.
EXPERIMENTAL PROCEDURES
Characterization of A-to-I RNA Editing Profiles
We downloaded RNA-seq BAM files of 5,672 patient tumor samples
across 17 TCGA cancer types and their related 564 non-tumor tissue sam-
ples (if available) from the University of California, Santa Cruz, Cancer Ge-
nomics Hub (CGHub; https://cghub.ucsc.edu). We also downloaded 740
BAM files of CCLE cell lines from CGHub. The detailed read mapping pro-
cedure (BAM generation) was previously described in TCGA marker papers
(Brennan et al., 2013; Cancer Genome Atlas Research Network, 2008,
2012, 2013; Cancer Genome Atlas Network, 2012a, 2012b; Kandoth
et al., 2013).
We obtained a comprehensive collection of 1.4 million A-to-I RNA editing
sites from RADAR (http://rnaedit.com) (Ramaswami and Li, 2014). Note that
these RNA editing sites were directly called from RNA-seq data from normal
tissues and tumor samples, not from the comparison of editing profiles upon
ADAR perturbation. We re-annotated them by ANNOVAR (Wang et al., 2010)
and then filtered 4,000 sites annotated in dbSNP (version 137), COSMIC,
and TCGA somatic mutations. On the basis of the RNA-seq reads mapped
to the human reference genome (hg19), the editing level at a specific site in
a given sample was calculated as the number of edited reads divided by the
total number of reads (Ramaswami et al., 2013), and only the nucleotides
with base qualityR20 were used. Those editing sites with at least three edited
reads in at least 3 samples per tissue type were considered to be detected
RNA editing sites. To ensure adequate statistical power, we further identified
the informative RNA editing sites among the detected RNA editing sites by
requiring at least 30 samples (including normal samples if available) with
coverage R 10 in a tissue/tumor type. Thus, given a cancer type, the tumor
samples and their related normal samples had the same set of informative
RNA editing sites in our analysis. To further rule out the possibility of potential
contamination due to undetected SNPs or somatic mutations, we obtained
whole-genome sequencing data from International Cancer Genome Con-
sortium and whole-exome sequencing data from TCGA for the cancer types
we surveyed and assessed if there were some potential mutational signals
at informative RNA editing sites. We found potential mutational signals at
only 310 sites out of 112,572 across the 17 cancer types (0.28%) and excluded
them from our analysis.tes
multiple cancer types. For each cancer type, the gray box indicates not sig-
types (FDR < 0.2, DiffR 5%), the green box indicates the significant differential
tion with the overall survival (FDR < 0.2, DiffR 5%).
diting events in AZIN1S367G (CRC subtype: CIN, chromosomal instability; MSI,
ype: CIN, chromosomal instability; EBV, Epstein-Barr virus positive; GS, ge-
4G (E). The boxes show the median ± 1 quartile, with whiskers extending to the
G-CIMP, glioma CpG island methylation phenotype.
and Table S3.
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Comparisons of RNA Editing Patterns between Cancer and Normal
Samples
For the comparison between tumor and normal samples, we required the infor-
mative RNA editing sites with at least five pairs of tumor and normal samples
with coverageR 10. If sufficient matched normal samples in which a site had
adequate coverage were not available, the site was excluded from our anal-
ysis. We used theWilcoxon test to detect RNA editing sites with differential ed-
iting between tumor and normal samples and defined significantly differential
editing sites as FDR < 0.05 and DiffR 5%. TCGAmRNA expression data were
obtained from Synapse: syn300013 (Omberg et al., 2013). We used the paired
Student’s t test to detect differentially expressed ADAR enzymes between
normal and tumor samples.
Identification of Clinically Relevant RNA Editing Sites
We obtained clinical information, including tumor subtypes, disease stage,
and patient overall survival time, from TCGA marker papers or the TCGA
data portal (https://tcga-data.nci.nih.gov/tcga/). We used the Wilcoxon test
or Kruskal-Wallis nonparametric ANOVA to detect RNA editing sites with dif-
ferential editing among different tumor subtypes and considered FDR < 0.01
to be statistically significant. We used the Wilcoxon test or Kruskal-Wallis
nonparametric ANOVA to detect RNA editing sites with differential editing
among different tumor stages and considered FDR < 0.05 to be statistically
significant. We used the univariate Cox test to examine whether the RNA edit-
ing level was significantly correlated with patient survival and considered
FDR < 0.05 to be statistically significant. We chose different FDR cutoffs on
the basis of the signal abundance in each analysis. Groups with fewer than
five samples were excluded from the analysis. We required a Diff R 5% for
at least two groups, thereby ensuring a sufficient biological difference. The
gene-annotation-based RNA type of an RNA editing site was annotated by
ANNOVAR, and the sequence repetitive status and evolutionary conservation
status (i.e., the conservation among humans, chimpanzees, and macaques)
were annotated as in RADAR (Ramaswami and Li, 2014). To test the effect
of tumor purity, we obtained the tumor purity data on the basis of ABSOLUTE
from Synapse: syn1710466 (Carter et al., 2012) and repeated the analysis with
the tumor purity as a covariate in the ANOVA. We repeated the above analysis
for the nonsynonymous RNA editing sites only and considered FDR < 0.2 to
indicate statistical significance. We then ranked the nonsynonymous RNA ed-
iting sites on the basis of the number of cancer types with detected
significance.
To assess if clinically relevant RNA editing sites are enriched in some RNA
regions, we performed a coverage-dependent permutation test. First, for
each cancer type, we classified all the informative RNA editing sites into ten
coverage groups (each with the same number of editing sites) on the basis
of the median coverage of a given RNA editing site across all sufficiently
covered samples. Second, given the numbers of clinically relevant sites
observed in each group, we randomly selected the same number of RNA edit-
ing sites as ‘‘pseudo clinically relevant sites,’’ so that the whole pseudo set
would have the same coverage distribution as the true clinically relevant sites.
We then counted the frequencies of pseudo clinically relevant sites for each
type of RNA region. We repeated this process 1,000 times, and on the basis
of the obtained distributions of these permutations, we assessed the statistical
significance of the enrichment of the clinically relevant sites relative to the
random expectation (defined as the frequency of permutations with the num-
ber of pseudo clinically relevant sites no fewer than the observed true clinically
relevant sites). We did this analysis for each cancer type separately.
Sequenom Validation
Four selected RNA editing sites, AZIN1S367G, COPAI164V, COG3I635V, and
GRIA2R764G, were validated on in-house breast cancer samples by SequenomFigure 5. Sequenom Validation and Functional Effects of Nonsynonym
(A) Sequenom validation of AZIN1S367G. (Top) Results of a group of samples at cDN
the AG genotype of a sample. (Bottom) Results of an individual sample in cDNA an
but only one ‘‘A’’ peak in gDNA.
(B) The effects of AZIN1S367G, GRIA2R764G, and COG3I635V in MCF10A cell viabil
(C) The effects of AZIN1S367G, GRIA2R764G, and COG3I635V in BaF3 cell viability a
Two-sided t test was used to assess the difference. Error bars denote ± SEM. *p
CMassARRAY at the MD Anderson Sequenome Core Facility, as previously
described (Liang et al., 2012).
Generation of Stable BaF3 and MCF10A Cell Lines
The mutant open reading frames corresponding to the RNA editing sites in
AZIN1, GRIA2 (the mutation was introduced at the R764G site only and the
codon at Q607R remained asWTCAG), andCOG3weremade by site-directed
mutagenesis and confirmed by Sanger sequencing. Virus were produced by
transfecting human embryonic kidney 293PA (HEK293PA) cells with the GFP
control vectors or pHAGE-V5-puromycin expression vectors (carrying
AZIN1-WT, AZIN1-S367G, GRIA2-WT, GRIA2-R764G, COG3-WT, or COG3-
I635V), and the Lentiviral Packaging Mix (psPAX2 and pMD2.G). BaF3 cells
were transduced by the virus and were added RPMI 1640 medium/5% FBS
in the low IL-3 (0.0001 ng/ml) and put back into the incubator for 4 weeks, fol-
lowed by selection with puromycin (0.6 mg/ml) and IL-3 withdrawal. Stable
Ba/F3 cells weremaintained inmediumwithout IL-3. MCF10A cells were trans-
duced by the virus, followed by selection with puromycin (0.6 mg/ml). Stable
MCF10A cells weremaintained in completed Dulbecco’smodified Eagle’sme-
dium (DMEM)/F12 (Invitrogen) full medium with 5% horse serum (Invitrogen),
20 ng/ml EGF (Peprotech), 10 mg/ml insulin (Sigma), 100 ng/ml Cholera Toxin
(Sigma), and 0.5 mg/ml hydrocortisone. After 7 days of antibiotic selection,
expression of the constructs was verified by western blots.
Cell Extract Preparation and Western Blotting
Whole-cell lysates for western blotting were extracted with RIPA (25 mM Tris-
HCl [pH 7.6], 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS,
protease, and phosphatase inhibitor cocktail). Cell lysates (20 ug) were loaded
onto 10% SDS-PAGE and transferred to a polyvinylidene fluoride membrane,
and protein expression was depicted with an enhanced chemiluminescence
western blot detection kit (Amersham Biosciences). Antibodies used were
AZIN1, antizyme inhibitor 1Polyclonal antibody (Proteintech), GRIA2, AMPA
receptor (GluR 2) (E1L8U) Rabbit mAb (Cell Signaling Technology), COG3
polyclonal antibody (Proteintech), V5 Tag Mouse Monoclonal Antibody (Life
Technologies), and ERK2 (Santa Cruz Biotechnology).
BaF3 and MCF10A Cell Viability Assay
BaF3 cells were transduced by the virus and resuspended in BaF3 low IL-3
medium (0.0001 ng/ml). Then the cells were transferred to a 96-well plate,
and the assays were performed at weeks 1.5, 2, 3, and 4. Stable MCF10A
cell lines were seeded into 96-well plates, and the assays were performed at
days 0, 4, 8, 10, and 12. CellTiter-Glo (Promega) was added to access cell
viability according to the manufacturer’s instructions. The cell viability mea-
surement was also performed on the basis of cell counting after trypsin diges-
tion. The significance of differenceswas analyzed with Student’s t test, and p <
0.05 was considered statistically significant.
Apoptosis Assay
Cells (1.5 3 104) were seeded into six-well plates for 24 hr before incubation
with MCF10A full medium, MEBM added BPE (Lonza), or DMEM without
glucose and L-glutamine for another 24 hr. Apoptosis-induced DNA fragmen-
tation was measured using the Cell Death Detection ELISA Kit (Roche Applied
Science) according to the manufacturer’s instructions. Apoptosis-induced the
active form of caspase-3 was tested using the PE Rabbit Anti-Active Caspase-
3 (BD Biosciences) according to the manufacturer’s instructions. The BD
Canto II analyzer was used to read active caspase-3 in the PE channel.
Wound Healing Assay
MCF10A cells (3.53 104) were seeded into 96-well ImageLock plates for 24 hr
in DMEM/F12 medium included with 1% horse serum, 4 ng/ml EGF, 2 mg/mlous RNA Editing Sites on Cell Viability
A and genomic DNA (gDNA), respectively, where each blue symbol represents
d gDNA, respectively, where there are one ‘‘A’’ peak and one ‘‘G’’ peak in cDNA
ity assays.
ssays.
< 0.05, **p < 0.001, ***p < 0.0001. See also Figure S3.
ancer Cell 28, 515–528, October 12, 2015 ª2015 Elsevier Inc. 525
AB
Figure 6. Effects of Nonsynonymous RNA Editing Sites on Drug Sensitivity
(A) Spontaneously transformed Ba/F3 cells (negative control), Ba/F3 cells stably expressing AZIN1 and AZIN1S367G, GRIA2 and GRIA2R764G, and COG3 and
COG3I635V were screened against the drug library with or without IL-3 for 72 hr. Dose-response curves are shown for the IGF-1R inhibitor BMS536924, the MEK
(legend continued on next page)
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insulin, 20 ng/ml Cholera Toxin, and 0.1 mg/ml hydrocortisone. Automated
96-well cell migration (scratch wound) on IncuCyte was analyzed using the In-
cuCyte Cell Migration Kit (Essen BioScience), which comprises a 96-pin
wound-making tool (WoundMaker), a Cell Migration Analysis softwaremodule,
and a starter batch of 96-well ImageLock plates.
Ba/F3 Drug Screening Assay
The IL-3-dependent Ba/F3 parental cell line was maintained in RPMI 1640 me-
dium containing 5% FBS and 5 ng/ml IL-3. The spontaneously transformed
Ba/F3 cell line was maintained in RPMI 1640 medium containing 5% FBS
without IL-3. Stable Ba/F3 cell lines expressing the WT and edited genes
were obtained and maintained by selection of puromycin (0.6 mg/ml) and
IL-3 withdrawal. The 145-compound library was purchased from the John
S. Dunn Gulf Coast Consortium for Chemical Genomics. These compounds
were dissolved in DMSO as 10 mM stock solutions. The day before treatment,
cells (1 3 104) were seeded in 96-well plates in medium with or without IL-3.
Eight serial dilutions of each compound were prepared in media, and final
drug concentrations ranged from 0–10 mM. Cells were treated with DMSO or
drug compounds in the presence or absence of IL-3 for 72 hr. Cell viability
was determined using PrestoBlue (Promega) for mitochondrial dehydroge-
nase activity. Drug screening was repeated independently to ensure the repro-
ducibility of the results.
To comprehensively assess the effects of RNA editing sites on drug sensi-
tivity, we downloaded the drug screening data from CCLE (http://www.
broadinstitute.org/ccle/home) and calculated the correlations between the
RNA editing level and IC50.
ACCESSION NUMBERS
The accession number for the RNA editing data reported in this paper is Syn-
apse: syn2374375.
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